造影剂更迭时代:预用药在减少血管内造影剂复发性超敏反应中是否仍有角色?
本文综述碘对比剂超敏反应(HR)的预用药问题。在非离子低渗对比剂时代,皮质类固醇和/或H1抗组胺药预用药的证据质量低,对中重度HR效果欠佳,突破反应常见且可能严重。准确记录HR并更换对比剂(最好换不同侧链)效果更好;预用药可能仅用于既往严重HR且致敏对比剂不明时的紧急影像检查。
要点
- 非离子低渗对比剂时代,预用药预防中重度HR的证据质量低、效果欠佳。
- 准确记录超敏反应并更换对比剂(优先不同侧链)比预用药效果更好。
- 预用药可能仅适用于既往严重HR且致敏对比剂无法追溯的紧急影像检查。
核心结论
- 在非离子低渗碘对比剂时代,预用药预防复发性超敏反应的证据质量低,对中重度反应效果欠佳,突破反应常见且可能严重。
- 准确记录超敏反应并更换特定碘对比剂(最好经过敏评估后换用不同侧链)可获得更好结果,预用药仅可能在特定紧急场景中有 niche 指征。
研究设计与样本
- 综述性文章,检索范围与纳入文献数量原文未报告。
临床应用与阅片要点
- 对有既往超敏反应或急性过敏史的患者,应准确记录反应细节并考虑更换碘对比剂,优先选择不同侧链。
- 预用药对中重度超敏反应的预防效果有限,且突破反应可能严重,不应常规依赖。
- 在紧急影像检查中,若患者有既往严重超敏反应且致敏对比剂无法追溯或未知,可考虑预用药。
局限性
- 原文指出预用药在非离子低渗对比剂时代证据质量低,且在高风险患者特定临床场景中的数据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Iodine-based contrast media (ICM) are an integral part of CT or angiography. Its use can lead to hypersensitivity reactions (HR), and the risk of recurrence is increased in patients with a prior HR or history of acute allergy. Premedication with corticosteroids and/or H1-antihistamines, dating from the era of ionic high-osmolar ICM, has been popular amongst radiologists. However, when used with nonionic low-osmolar ICM, the quality of evidence is low, efficacy in moderate-severe HR is suboptimal, frequent breakthrough reactions occur and can be severe, and its use can increase costs. There is a paucity of data for premedication use in high-risk patients in specific clinical scenarios, and, in general, accurate HR documentation and changing of the specific ICM, preferably with a different sidechain after allergologic evaluation, leads to better results. The imaging setting (hospital or clinic) and level of support in emergency situations will likely be important determinants of its use. There may be a niche indication for premedication in stressful emergency imaging of patients with a prior severe HR in which the culprit ICM is untraceable or unknown.
引用
- van der Molen AJ, Singh CL, Vega F, et al. In an era of changing contrast agents, is there still a role for premedication in specific clinical scenarios to reduce recurrent hypersensitivity reactions after intravascular contrast agent administration? Eur J Radiol. 2026. PMID: 42659895. doi:10.1016/j.ejrad.2026.113192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。